Gyre Therapeutics (GYRE) Non-Current Deffered Revenue (2010 - 2026)
Gyre Therapeutics (GYRE) reported Non-Current Deffered Revenue of $840000.0 for Q1 2026, down 7.18% year-over-year from $905000.0 in Q1 2025, and down 1.41% quarter-over-quarter from $852000.0 in Q4 2025.
Gyre Therapeutics (GYRE) Non-Current Deffered Revenue (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has 12 years of Non-Current Deffered Revenue data on file, last reported at $840000.0 in Q1 2026.
- Non-Current Deffered Revenue for Q1 2026 came in at $840000.0, down 7.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $840000.0 (down 7.18% YoY), and the FY2025 annual result was $852000.0, down 8.19% from the prior year.
- Non-Current Deffered Revenue eased to $840000.0 in Q1 2026 per GYRE's latest filing, from $852000.0 in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $928000.0 in Q4 2024 and troughed at $118000.0 in Q4 2022.
- A 5-year average of $562363.6 and a median of $840000.0 in 2026 frame the typical range for Non-Current Deffered Revenue.
- On a YoY basis, Non-Current Deffered Revenue climbed as much as 368.11% in 2025 and fell as far as 8.19% in 2025.
- A 5-year view of Non-Current Deffered Revenue shows it stood at $118000.0 in 2022, then surged by 80.51% to $213000.0 in 2023, then surged by 335.68% to $928000.0 in 2024, then dropped by 8.19% to $852000.0 in 2025, then fell by 1.41% to $840000.0 in 2026.
- Business Quant data shows GYRE's Non-Current Deffered Revenue at $840000.0 in Q1 2026, $852000.0 in Q4 2025, and $866000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Gyre Therapeutics | 554.75 Mn | 540.62 Mn | 8.38 Mn | 840,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 840,000.00 |
| Dec 31, 2025 | 852,000.00 |
| Sep 30, 2025 | 866,000.00 |
| Jun 30, 2025 | 884,000.00 |
| Mar 31, 2025 | 905,000.00 |
| Dec 31, 2024 | 928,000.00 |
| Sep 30, 2024 | 185,000.00 |
| Jun 30, 2024 | 192,000.00 |
| Mar 31, 2024 | 203,000.00 |
| Dec 31, 2023 | 213,000.00 |
| Dec 31, 2022 | 118,000.00 |
| Dec 31, 2018 | 174,000.00 |
| Sep 30, 2018 | 161,000.00 |
| Jun 30, 2018 | 140,000.00 |
| Mar 31, 2018 | 135,000.00 |
| Dec 31, 2016 | 7,000.00 |
| Sep 30, 2016 | 18,000.00 |
| Jun 30, 2016 | 73,000.00 |
| Mar 31, 2016 | 183,000.00 |
| Dec 31, 2015 | 48,000.00 |